“We are extremely encouraged by the tremendous progress we have made, in a short time, to develop single domain antibody therapeutics with the potential to deliver highly targeted compounds that ...

or single-domain antibody (VHH) format. Partners also have access to the IPA’s proprietary in-house disease and naïve human or llama phage libraries. • ImmunoPrecise’s affinity maturation ...

Originally derived from camelid heavy chain antibodies, single domain or VHH antibodies can bind epitopes that are inaccessible to conventional monoclonal antibodies due to their small size. Because ...

and chromosomal engineering technologies to develop next-generation genetic models that accelerate antibody discovery.

In June 2024, Jiangsu Alphamab entered into a research and collaboration agreement with ArriVent BioPharma, Inc. to use Jiangsu Alphamab's proprietary linker-payload (Alphatecan) and glycan-specific ...

Nanobodies: Nanobodies are single-domain antibodies obtained from camelid antibodies. They are small in size and can bind to cryptic epitopes. Antibody-Drug Conjugates (ADCs): These antibodies are ...

An antibody discovery platform revealed more than 60 monoclonal antibodies specific to patients with alpha-gal syndrome, ...